The End of DEA’s Most Powerful Enforcement Tool Against Pharmacies: A Federal Circuit Court Just Dismantled DEA’s Use of the “Corresponding Responsibility” Doctrine

The Fifth Circuit’s opinion in Neumann’s Pharmacy, L.L.C. v. Drug Enforcement Administration is more than a routine administrative law decision. It represents a potentially significant recalibration of DEA’s long-asserted “corresponding responsibility” and “red flag” doctrine—the theory that pharmacists share responsibility with prescribing practitioners to ensure that controlled substance prescriptions are issued for a legitimate medical purpose. For pharmacies and pharmacists, this ruling will meaningfully reshape the CSA compliance landscape.

Understanding the “Corresponding Responsibility” Doctrine

Under DEA regulations, the prescriber is principally responsible for ensuring a prescription for a controlled substance is issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. However, the regulations further provides that a pharmacist who fills a prescription bears a “corresponding responsibility” to ensure that standard is met.

Over the past several years, DEA has relied heavily on this doctrine in enforcement actions against pharmacies—particularly in opioid-related investigations. In practice, the agency has often argued that pharmacists must resolve “red flags” that are indicative of diversion or misuse and that failure to do so can justify revocation or suspension of a DEA registration. Critics have long argued that the DEA’s application of the “corresponding responsibility” doctrine sometimes drifts into second-guessing medical judgments or imposing vague, after-the-fact compliance standards.

See my November 13th and November 17th posts for more context and information on the corresponding responsibility and red flag doctrine.

How the Fifth Circuit Reframed the Doctrine

In Neumann’s Pharmacy, the Fifth Circuit took a hard look at how the DEA applied corresponding responsibility in the administrative proceeding. While the court did not eliminate the doctrine, its opinion meaningfully constrained how it can be enforced:

1. Objective Evidence Over Hindsight

The court emphasized that DEA must ground its findings in concrete, record-based evidence that prescriptions were objectively illegitimate—not merely suspicious in retrospect. This narrows the agency’s ability to rely on generalized indicators or broad statistical patterns as substitutes for prescription-specific proof.

2. Clear Notice of What Constitutes a “Red Flag”

A central problem in many DEA cases is the elasticity of the “red flag” concept. The Fifth Circuit signaled that pharmacies must have fair notice of what conduct crosses the line. Vague or evolving enforcement theories cannot serve as the basis for severe penalties like revocation. This aspect of the opinion pressures the DEA to articulate clearer standards rather than rely on open-ended expectations that pharmacists should “know it when they see it.”

3. Limits on Burden Shifting

The decision also pushes back on the subtle burden-shifting that sometimes occurs in DEA proceedings. Corresponding responsibility does not mean pharmacists must conclusively disprove every possible concern. The agency retains the burden to demonstrate, with substantial evidence, that the pharmacy knowingly filled prescriptions outside the bounds of legitimacy.

Practical Impact on DEA Enforcement

The ruling may influence DEA enforcement in several important ways:

• More Disciplined Administrative Records: DEA investigators and administrative law judges will likely need to develop more robust, prescription-specific evidence when invoking corresponding responsibility. Broad narratives about opioid abuse trends will not be enough.

• Greater Litigation Risk for the Agency: By signaling a willingness to scrutinize the DEA’s reasoning closely, the Fifth Circuit increases the likelihood that registrants will challenge enforcement actions rather than settle or surrender registrations.

• Regional Ripple Effects: Although binding only within the Fifth Circuit, the decision may be cited persuasively in other jurisdictions. If similar reasoning is adopted elsewhere, the practical scope of the corresponding responsibility doctrine could narrow nationwide.

What This Means for Pharmacies

Importantly, Neumann’s Pharmacy does not eliminate pharmacists’ obligations. The corresponding responsibility regulation remains in force. Pharmacies must still:

• Identify and evaluate red flags

• Document resolution of concerns

• Maintain robust compliance systems

• Train staff on controlled substance policies

However, the decision reinforces that DEA expectations must be grounded in law and evidence—not in shifting or undefined enforcement theories.

Going Forward

The Fifth Circuit did not dismantle the DEA’s authority. But in scrutinizing how corresponding responsibility was applied, it introduced meaningful guardrails. The opinion underscores a key principle: enforcement power under the CSA is substantial, but it is not boundless. For an agency that has relied heavily on the corresponding responsibility doctrine in combating diversion, the decision in Neumann’s Pharmacy may mark the beginning of a more constrained—and more clearly defined—era of pharmacy oversight.